65,437 trials
Dry Eye Disease
Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Day 90 — 41.77; 40.92; -16.88; -15.97 score on a scale
Hepatocellular Carcinoma
Primary: Subjects With Treatment Emergent Adverse Events — 23 participants
Sleep Disordered-breathing
Primary: Failure Rate of Sleep Study — 6; 6 percentage of participants
End Stage Renal Disease
Primary: Serum 25D Level — 49.8; 38.3; 27.3 ng/ml
Hyperlipidemias
Primary: Triglyceride Levels — 135.5; 108.3; 152.7; 109 milligram/deciliter
Infertility
Primary: Fetal Heart Activity 1 Month Post Embryo Transfer — 0; 4 participants with fetal heart activity
Migraine Prophylaxis
Primary: Change From Baseline in Migraine Period Frequency Per 28 Days in Treatment Phase (LOCF) — -2.94; -2.73; -3.31; -3.00 Migraine period
Bone Diseases
Primary: Resorption of Graft Material (GR) Compared at 24 Months — 51; 47 percentage of resorption — p=<0.01
Diabetic Macular Edema
Primary: Percentage Change in Retinal Thickness in the Study Eye at 6 Months Compared to Baseline — -7.89 percentage change in retinal thickness
Asthma
Primary: Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) — 1.21; 1.39; 1.12; 1.33 L*hour — p=<0.0001
End-stage Renal Failure
Primary: Dialysability of Dotarem® in Dialysed Patients — -88.2; -93.4; -97.1; -94.8 percent change in Gd concentration
Acute Kidney Injury
Primary: Acute Kidney Injury Measured by Kidney Diseases: Improving Global Outcomes (KDIGO) AKI Serum Creatinine Criteria — 43; 36 participants
Postoperative Pain
Primary: Pain Score (NRS: Numerical Rating Scale) — 4.50; 4.81; 4.17 units on a scale
Refractive Error
Primary: Mean Change From Baseline in Investigator Rated Lid Papillae Maximum Score at Day 90 — 2.3; 2.3; 2.2; 2.2 units on a scale
Multiple Myeloma · Non-Hodgkin Lymphoma · Acute Myeloid Leukemia
Primary: Subjects With Treatment Emergent Adverse Events — 20 participants